Abstract
Eosinophils are innate effector cells associated with allergic inflammation. Their development and survival is largely dependent on IL-5 and the common beta chain (βc ) of the IL-5 receptor that serves as docking site for several proteins that mediate down-stream signaling cascades including JAK/STAT, PI3 kinase, NFκB, and RAS-MAP kinase pathways. The relative contribution of these signaling pathways for eosinophil development and homeostasis in vivo are poorly understood. Here, we investigated the role of GRB2, an adaptor protein that binds to βc and other proteins and elicits the RAS-MAP kinase pathway. By using GRB2 inhibitors and inducible deletion of the Grb2 gene in mouse eosinophils we demonstrate that GRB2 plays a critical role for development of eosinophils from bone marrow precursors. Furthermore, Aspergillus fumigatus-induced allergic lung eosinophilia was significantly reduced in mice with induced genetic deletion of Grb2. Our results indicate that GRB2 is important for eosinophil development in steady-state conditions and during allergic inflammation. Based on these findings pharmacologic GRB2 inhibitors may have the potential to dampen tissue eosinophilia in various eosinophil-associated diseases.